Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Share-based Compensation (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Share-based Compensation data on record, last reported at $273000.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 60.15% year-over-year to $273000.0; the TTM value through Sep 2025 reached $1.5 million, down 67.75%, while the annual FY2024 figure was $3.5 million, 21.6% down from the prior year.
  • Share-based Compensation reached $273000.0 in Q3 2025 per NWBO's latest filing, down from $364000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.8 million in Q1 2021 and bottomed at $273000.0 in Q3 2025.
  • Average Share-based Compensation over 5 years is $1.9 million, with a median of $1.2 million recorded in 2024.
  • The widest YoY moves for Share-based Compensation: up 10045.71% in 2021, down 96.75% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $866000.0 in 2021, then surged by 195.27% to $2.6 million in 2022, then tumbled by 38.4% to $1.6 million in 2023, then plummeted by 71.17% to $454000.0 in 2024, then tumbled by 39.87% to $273000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $273000.0 in Q3 2025, $364000.0 in Q2 2025, and $385000.0 in Q1 2025.